Blood samples from NSCLC patients treated with nivolumab revealed that Tregs were more present in the blood of non-responders [40], consistent with Kamada et al.’s [41] study that demonstrated the dampening effect of Tregs on anti-PD-1 response. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.